Awakn Life Sciences CEO, Anthony Tennyson, Joins Dustin Robinson of Iter Investments for 'The Investor Hotseat' via Live Stream on May 26th Company News
COMPASS Pathways presents largest ever study of psilocybin therapy, at American Psychiatric Association annual meeting Psychedelics Investing
U.K. Member of Parliament Crispin Blunt To Inaugurate Psilocybin Cultivation Facility At Optimi Health Grand Opening Psychedelics Investing
Awakn Life Sciences Completes World's First Ketamine Treatment Study for a Range of Behavioral Addictions Company News
Seelos Therapeutics Receives a Notice of Allowance in the U.S. for an Additional Patent for SLS-007 Psychedelics Investing
Optimi Health Acquires Extensive Catalog of Psychedelic and Functional Mushroom Genetics Psychedelics Investing
Awakn Life Sciences Appoints UK Leader in Addictions Psychiatry, Dr. Arun Dhandayudham, as Chief Medical Officer Company News
Universal Ibogaine Co-Founder Dr Alberto Sola to Present at upcoming Research to Reality Conference Pharmaceutical Investing
Albert Labs' Pre-Clinical Analytical and Toxicological Research Supports Company's Forthcoming Studies Pharmaceutical Investing
